The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  2011-01-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2010-04-278853PMID 21106982
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.

  2011cited by this paper
• Bortezomib Resistance in Mantle Cell Lymphoma Is Associated with Expression of a Plasmacytoid Differentiation Program.

  2009cited by this paper
• Activation of the endoplasmic reticulum stress-associated transcription factor x box-binding protein-1 occurs in a subset of normal germinal-center B cells and in aggressive B-cell lymphomas with prognostic implications.

  2009cited by this paper
• Mantle cell lymphoma: biological insights and treatment advances.

  2009cited by this paper
• Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

  2009cited by this paper
• ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

  2009cited by this paper
• 2‐D PAGE‐based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma

  2009cited by this paper
• Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells

  2009cited by this paper
• How I treat mantle cell lymphoma.

  2009cited by this paper
• ORIGINAL ARTICLE Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells

  2009cited by this paper
• NRF2 at the Interface of Oxidative and Endoplasmic Reticulum Stress Pathways Is a Critical Integrator of Bortezomib Response in Mantle Cell Lymphoma in Vitro and In Vivo.

  2009cited by this paper
• Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.

  2009cited by this paper
• Cyclin D1 mediates resistance to apoptosis through upregulation of molecular chaperones and consequent redistribution of cell death regulators

  2008cited by this paper
• Therapy of mantle cell lymphoma: current standards and future strategies.

  2008cited by this paper
• Targeting Hsp90: small-molecule inhibitors and their clinical development.

  2008cited by this paper
• Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

  2008cited by this paper
• Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation

  2008cited by this paper
• The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

  2008cited by this paper
• GRP78: a chaperone with diverse roles beyond the endoplasmic reticulum.

  2008cited by this paper
• Point Mutation of the Proteasome β5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line

  2008cited by this paper
• Untangling the unfolded protein response

  2008cited by this paper
• Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.

  2008cited by this paper
• Mechanisms of proteasome inhibitor action and resistance in cancer.

  2008cited by this paper
• IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells

  2008cited by this paper
• Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.

  2008cited by this paper
• Selective Inhibition of IκB Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level1

  2007cited by this paper
• The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.

  2007cited by this paper
• Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics

  2007cited by this paper
• How I treat mantle cell lymphoma.

  2007cited by this paper
• Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells.

  2007cited by this paper
• ER chaperones in mammalian development and human diseases

  2007cited by this paper
• Gene expression analysis of B‐lymphoma cells resistant and sensitive to bortezomib *

  2006cited by this paper
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

  2006cited by this paper
• Mediators of endoplasmic reticulum stress‐induced apoptosis

  2006cited by this paper
• Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90

  2006cited by this paper
• The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.

  2006cited by this paper
• Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.

  2006cited by this paper
• Localization of GRP78 to mitochondria under the unfolded protein response.

  2006cited by this paper
• Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.

  2006cited by this paper
• Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells.

  2006cited by this paper
• Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

  2005cited by this paper
• Intracellular Protein Degradation and Its Therapeutic Implications

  2005cited by this paper
• Antimyeloma activity of heat shock protein-90 inhibition.

  2005cited by this paper
• HSP90 and the chaperoning of cancer

  2005cited by this paper
• Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers.

  2005cited by this paper
• IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A

  2005cited by this paper
• Herp Is Dually Regulated by Both the Endoplasmic Reticulum Stress-specific Branch of the Unfolded Protein Response and a Branch That Is Shared with Other Cellular Stress Pathways*

  2004cited by this paper
• The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress.

  2003cited by this paper
• Orchestrating the unfolded protein response in health and disease.

  2002cited by this paper
• Translational control in the endoplasmic reticulum stress response.

  2002cited by this paper
• Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation.

  2000cited by this paper
• Functional and Genomic Analyses Reveal an Essential Coordination between the Unfolded Protein Response and ER-Associated Degradation

  2000cited by this paper
• Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME.

  1996cited by this paper

• Unraveling bortezomib resistance in multiple myeloma: insights from RNA-Seq and PI3K/mTOR pathway analysis

  2026cites this paper
• Role of TRIM24 in the regulation of proteasome-autophagy crosstalk in bortezomib-resistant mantle cell lymphoma

  2025cites this paper
• Improving data interpretability with new differential sample variance gene set tests

  2025cites this paper
• Improving data interpretability with new differential sample variance gene set tests

  2024cites this paper
• A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5.

  2023cites this paper
• Targeted inhibition of protein synthesis renders cancer cells vulnerable to apoptosis by unfolded protein response

  2023cites this paper
• Cell surface expression of GRP78 and CXCR4 is associated with childhood high-risk acute lymphoblastic leukemia at diagnostics

  2022cites this paper
• iASPP suppression mediates terminal UPR and improves BRAF-inhibitor sensitivity of colon cancers

  2022cites this paper
• HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)

  2022cites this paper
• Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy

  2022cites this paper
• A quantitative high-throughput screen identifies compounds that lower expression of the SCA2-and ALS-associated gene ATXN2

  2022cites this paper
• Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma

  2022influential citation
• HSP90 inhibition downregulates DNA replication and repair genes via E2F1 repression

  2021cites this paper
• Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma

  2021cites this paper
• Targeting heat shock protein 90 for anti-cancer drug development.

  2021cites this paper
• MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway

  2021cites this paper
• Management of Drug Resistance in Mantle Cell Lymphoma

  2020cites this paper
• Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.

  2020cites this paper
• Proteostasis and Disease: From Basic Mechanisms to Clinics

  2020cites this paper
• Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma

  2020cites this paper
• Enhancement of cisplatin sensitivity in human breast cancer MCF-7 cell line through BiP and 14-3-3ζ co-knockdown

  2020cites this paper
• Adaptive response of resistant cancer cells to chemotherapy

  2020cites this paper
• Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myeloma

  2020cites this paper
• SNX-2112, an Hsp90 inhibitor, suppresses cervical cancer cells proliferation, migration, and invasion by inhibiting the Akt/mTOR signaling pathway

  2020cites this paper
• The emergence of drug resistance to targeted cancer therapies: Clinical evidence.

  2019cites this paper
• Research progress on therapeutic targeting of quiescent cancer cells

  2019cites this paper
• Stressed: The Unfolded Protein Response in T Cell Development, Activation, and Function

  2019cites this paper
• The Regulation of the Unfolded Protein Response and Its Roles in Tumorigenesis and Cancer Therapy

  2019cites this paper
• Resistance to Proteasome Inhibitor Therapy in Non-Hodgkin Lymphoma

  2019cites this paper
• Proteasome Inhibitors with a Focus on Bortezomib

  2018cites this paper
• The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma

  2018cites this paper
• Proteomic Profiling of Diffuse Large B-Cell Lymphomas

  2018cites this paper
• Resistance to proteasome inhibitors and other targeted therapies in myeloma

  2018cites this paper
• Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.

  2018cites this paper
• Virus and tumor microenvironment induced ER stress and unfolded protein response: from complexity to therapeutics

  2018cites this paper
• Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA

  2018cites this paper
• Resistance Mechanisms to Novel Therapies in Myeloma

  2018cites this paper
• Heat Shock Proteins and Endoplasmic Reticulum Stress

  2018cites this paper
• The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma

  2017cites this paper
• Heat Shock Proteins and Cancer.

  2017cites this paper
• NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

  2017cites this paper
• Emerging Role of the Unfolded Protein Response in Tumor Immunosurveillance.

  2017cites this paper
• Elucidating proteasome catalytic subunit composition and its role in proteasome inhibitor resistance

  2016cites this paper
• Homeostatic unbalance via HSPA 5 gene expression in HepG 2 C 3 A cells exposed to α-tomatine Desequilíbrio homeostático através da expressão do gene HSPA 5 em células HepG 2 / C 3 A exposto a α-tomatine

  2016cites this paper
• Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents

  2016cites this paper
• Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers

  2016cites this paper
• A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib.

  2016cites this paper
• Investigating Mechanisms Determining Cancer Cell Sensitivity to Carfilzomib and Novel Strategies to Overcome Resistance

  2016cites this paper
• Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB

  2015cites this paper
• Differential impact of bortezomib on HL-60 and K562 cells.

  2015cites this paper
• 17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways.

  2015cites this paper
• Controlling the unfolded protein response-mediated life and death decisions in cancer.

  2015cites this paper
• Oroxin B selectively induces tumor-suppressive ER stress and concurrently inhibits tumor-adaptive ER stress in B-lymphoma cells for effective anti-lymphoma therapy.

  2015cites this paper
• A Subset of Genes Can Distinguish between Bortezomib Responsive Versus Bortezomib Resistant Myeloma

  2015cites this paper
• Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

  2015cites this paper
• Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).

  2014cites this paper
• Regulation of the BH3-only protein NOXA in mantle cell lymphoma : relevance for novel treatment concepts

  2014cites this paper
• Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models

  2014cites this paper
• SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma.

  2014cites this paper
• Bases moleculars de l’activitat antitumoral de la lenalidomida en el limfoma de cèl•lules del mantell

  2014cites this paper
• Phenotypic Variation in Autism Spectrum Disorder: Insights from Syndromic Forms of Autism

  2014cites this paper
• Pre‐clinical efficacy of PU‐H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma

  2014cites this paper
• Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects

  2014cites this paper
• HKH40A downregulates GRP78/BiP expression in cancer cells

  2014cites this paper
• Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

  2014cites this paper
• Enhanced Antitumor Effects of Adenoviral-Mediated siRNA against GRP78 Gene on Adenosine-Induced Apoptosis in Human Hepatoma HepG2 Cells

  2014cites this paper
• Cancer Therapy : Preclinical Antitumoral Activity of Lenalidomide in In Vitro and In Vivo ModelsofMantleCell Lymphoma Involves theDestabilization of Cyclin D 1 / p 27 KIP 1 Complexes

  2014cites this paper
• The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: the role of ER stress.

  2014cites this paper
• Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma

  2014cites this paper
• Proteomics for systems toxicology

  2014cites this paper
• Identification and characterization of a proteasome deubiquitinase inhibitor

  2014cites this paper
• LYMPHOID NEOPLASIA SOX 11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma

  2014cites this paper
• 4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.

  2014cites this paper
• Targeting Mantle Cell Lymphoma with a Strategy of Combined Proteasome and Histone Deacetylase Inhibition

  2014cites this paper
• Endoplasmic reticulum stress in malignancy.

  2014cites this paper
• The role of the ubiquitin proteasome system in lymphoma.

  2013cites this paper
• Cancer Therapy : Preclinical Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma

  2013cites this paper
• The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies

  2013cites this paper
• Use of in vitro primary culture models to investigate the activity of standard and novel therapies in haematological malignancies

  2013cites this paper
• Antitumoral Activity of Lenalidomide in In Vitro and In Vivo ModelsofMantleCellLymphomaInvolvestheDestabilization

  2013cites this paper
• Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity.

  2013cites this paper
• Original article B-Crystallin in clear cell renal cell carcinoma: Tumor progression and prognostic significance

  2013cites this paper
• Antitumoral Activity of Lenalidomide in In Vitro and In Vivo Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27KIP1 Complexes

  2013cites this paper
• differentiation in aggressive mantle cell lymphoma SOX11 regulates PAX5 expression and blocks terminal B-cell

  2013cites this paper
• SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.

  2013cites this paper
• Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells

  2013influential citation
• Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.

  2013cites this paper
• Targeting the ubiquitin proteasome system: beyond proteasome inhibition.

  2013influential citation
• Drug combinations with proteasome inhibitors in antitumor therapy.

  2013cites this paper
• IRE1α dissociates with BiP and inhibits ER stress-mediated apoptosis in cartilage development.

  2013cites this paper
• Inhibition of Heat Shock Protein Response Enhances PS-341-Mediated Glioma Cell Death

  2012cites this paper
• Glucocorticoid and proteasome inhibitor impact on the leukemic lymphoblast: multiple, diverse signals converging on a few key downstream regulators.

  2012cites this paper
• Proteasome inhibitors in mantle cell lymphoma.

  2012influential citation
• The 26S proteasome complex: an attractive target for cancer therapy.

  2012cites this paper
• Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma

  2012cites this paper
• miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer

  2012cites this paper
• Molecular Biology of Mantle Cell Lymphoma

  2012cites this paper
• Proteasome Inhibitors in the Treatment of Multiple Myeloma

  2012cites this paper
• Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.

  2012cites this paper
• Heat Shock Protein 90 and Role of Its Chemical Inhibitors in Treatment of Hematologic Malignancies

  2012cites this paper